← Back to Home

Onvansertib colorectal cancer phase 2 follow-up extended; phase 3 launch still contingent on financing

Median progression-free survival has not yet been reached with the regimen containing onvansertib, suggesting the possibility of prolonged disease control. However, the magnitude of efficacy awaits confirmation from complete data, and the phase 3 trial planned for early 2027 is also contingent on funding.

By SURL BioNews

For patients with metastatic colorectal cancer, how long first-line treatment can keep the disease stable is an important measure when evaluating new therapies. Cardiff Oncology announced on November 12 that, with continued follow-up in a phase 2 study of the investigational oral drug onvansertib combined with existing regimens, median progression-free survival in the 30 mg group had still not been reached. The company is preparing for phase 3 confirmation but must secure additional financing before launching the trial.

This randomized phase 2 trial involves patients with RAS-mutated metastatic colorectal cancer receiving first-line treatment and evaluates the effect of adding onvansertib to FOLFIRI or FOLFOX chemotherapy in combination with bevacizumab. The combination the company plans to advance into phase 3 is 30 mg onvansertib plus FOLFIRI and bevacizumab. In this update, median progression-free survival in the pooled standard-of-care control group was approximately 11 months.

“Not yet reached” means that, based on current follow-up and statistical estimates, the time at which the progression-free survival curve falls to 50% cannot yet be determined. It does not mean that no patients have experienced disease progression, nor can it be directly translated into a specific number of additional months. In particular, because this comparison uses a pooled control group, the effects of different chemotherapy combinations and the number of patients in each group must be considered when interpreting efficacy.

As of September 28, six patients across the groups receiving FOLFIRI and bevacizumab remained on treatment: five from the groups receiving an additional 20 or 30 mg of onvansertib and one from the standard-of-care group. All patients remaining in the 30 mg group had been on treatment for at least 21 months, with the longest duration exceeding 29 months. This suggests that some patients can remain on the regimen for an extended period, but it cannot be taken as a typical outcome for the entire group.

Onvansertib is a PLK1 inhibitor. The central finding of this update is a signal of disease control with longer follow-up, but the announcement did not provide a new hazard ratio, confidence intervals, or a detailed safety analysis sufficient for a full assessment, nor did it demonstrate an overall survival benefit. The press release and its republication by Stock Titan on the same day both derive from the company announcement and do not constitute two independent clinical validations.

Cardiff expects to launch a phase 3 trial intended to support a registration application in the first quarter of 2027 after securing additional financing. Preparations are underway for trial execution, drug supply, and a RAS mutation companion diagnostic. Under the company’s plan, the study aims to use objective response rate to support potential accelerated approval, followed by progression-free survival to support full approval. These remain development goals and cannot be regarded as a commitment to approval by regulators.

Funding will also determine whether confirmatory testing can begin on schedule. As of the end of September, the company held approximately US$33.8 million in cash, cash equivalents, and short-term investments, which it estimated would fund operations through the end of the third quarter of 2027. However, the estimated funding available to sustain operations and the funding needed to launch phase 3 are separate matters. Whether this therapy can move toward clinical use will depend both on fundraising and on whether a larger trial can reproduce the efficacy findings and clarify the risks.

References

  1. Cardiff Oncology via GlobeNewswire
  2. Stock Titan / Cardiff Oncology syndicated release